These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
419 related items for PubMed ID: 33790418
21. Patterns of relapse as determined by 68Ga-PSMA ligand PET/CT after radical prostatectomy : Importance for tailoring and individualizing treatment. Henkenberens C, Derlin T, Bengel FM, Ross TL, Wester HJ, Hueper K, Kuczyk MA, Christiansen H, von Klot CA. Strahlenther Onkol; 2018 Apr; 194(4):303-310. PubMed ID: 29134231 [Abstract] [Full Text] [Related]
22. Regional Lymph Node Metastasis on Prostate Specific Membrane Antigen Positron Emission Tomography Correlates with Decreased Biochemical Recurrence-Free and Therapy-Free Survival after Radical Prostatectomy: A Retrospective Single-Center Single-Arm Observational Study. Amiel T, Würnschimmel C, Heck M, Horn T, Nguyen N, Budäus L, Knipper S, Wenzel M, Rauscher I, Eiber M, Wang H, Maurer T. J Urol; 2021 Jun; 205(6):1663-1670. PubMed ID: 33535796 [Abstract] [Full Text] [Related]
23. Lymph node staging with 68Ga-PSMA PET in patients with intermediate and high-risk prostate cancer suitable for radical prostatectomy managed in a prostate cancer unit. Maestroni UV, Campobasso D, Guarino G, Acampora A, Scarlattei M, Ziglioli F, Dinale F, Baldari G, Migliari S, Gasparro D, Ferretti S, Silini EM, Ruffini L. Chin Clin Oncol; 2023 Jun; 12(3):22. PubMed ID: 37417288 [Abstract] [Full Text] [Related]
24. Accuracy of 68Ga-PSMA PET-CT and PET-MRI in lymph node staging for localized prostate cancer. Barbosa ÁRG, Amaral BS, Lourenço DB, Bianco B, Gushiken FA, Apezzato M, Silva JF, Cunha MLD, Filippi RZ, Baroni RH, Lemos GC, Carneiro A. Einstein (Sao Paulo); 2022 Jun; 20():eAO6599. PubMed ID: 35584444 [Abstract] [Full Text] [Related]
28. Vesico-urethral anastomosis sampling: a forgotten tool for guiding salvage radiation after radical prostatectomy. Timm B, Farag M, Liodakis P, Angus D, Lim Joon D, Bolton D. BJU Int; 2021 May; 127 Suppl 1():23-29. PubMed ID: 33973332 [Abstract] [Full Text] [Related]
29. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT. Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE. Hell J Nucl Med; 2019 May; 22(1):6-9. PubMed ID: 30843003 [Abstract] [Full Text] [Related]
30. The superior detection rate of total-body [68Ga]Ga-PSMA-11 PET/CT compared to short axial field-of-view [68Ga]Ga-PSMA-11 PET/CT for early recurrent prostate cancer patients with PSA < 0.2 ng/mL after radical prostatectomy. Wang Y, Dong L, Zhao H, Li L, Huang G, Xue W, Liu J, Chen R. Eur J Nucl Med Mol Imaging; 2024 Jul; 51(8):2484-2494. PubMed ID: 38514483 [Abstract] [Full Text] [Related]
31. Site-specific relapse patterns of patients with biochemical recurrence following radical prostatectomy assessed by 68Ga-PSMA-11 PET/CT or 11C-Choline PET/CT: impact of postoperative treatments. Devos G, Witters M, Moris L, Van den Broeck T, Berghen C, Devlies W, De Meerleer G, Goffin K, Jentjens S, Albersen M, Van Poppel H, Everaerts W, Joniau S. World J Urol; 2021 Feb; 39(2):399-406. PubMed ID: 32417995 [Abstract] [Full Text] [Related]
32. 68Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer. Herlemann A, Wenter V, Kretschmer A, Thierfelder KM, Bartenstein P, Faber C, Gildehaus FJ, Stief CG, Gratzke C, Fendler WP. Eur Urol; 2016 Oct; 70(4):553-557. PubMed ID: 26810345 [Abstract] [Full Text] [Related]
33. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy. Schmidt-Hegemann NS, Fendler WP, Buchner A, Stief C, Rogowski P, Niyazi M, Eze C, Li M, Bartenstein P, Belka C, Ganswindt U. Radiat Oncol; 2017 Nov 10; 12(1):176. PubMed ID: 29126446 [Abstract] [Full Text] [Related]
36. Baseline PSMA-PET/CT as a predictor of PSA persistence following radical prostatectomy in high-risk nonmetastatic prostate cancer patients receiving neoadjuvant therapy. Du X, Dong Y, Liu J, Su Y, Zhu Y, Pan J, Dong B, Chen R, Liu J, Tong Z, Pienta KJ, Rowe SP, Dong L, Xue W. Prostate; 2023 Aug 10; 83(11):1112-1120. PubMed ID: 37165552 [Abstract] [Full Text] [Related]
37. Interobserver variability, detection rate, and lesion patterns of 68Ga-PSMA-11-PET/CT in early-stage biochemical recurrence of prostate cancer after radical prostatectomy. Miksch J, Bottke D, Krohn T, Thamm R, Bartkowiak D, Solbach C, Bolenz C, Beer M, Wiegel T, Beer AJ, Prasad V. Eur J Nucl Med Mol Imaging; 2020 Sep 10; 47(10):2339-2347. PubMed ID: 32157427 [Abstract] [Full Text] [Related]
40. Preoperative PSMA-PET/CT as a predictor of biochemical persistence and early recurrence following radical prostatectomy with lymph node dissection. Baas DJH, Schilham M, Hermsen R, de Baaij JMS, Vrijhof HJEJ, Hoekstra RJ, Sedelaar JPM, Küsters-Vandevelde HVN, Gotthardt M, Wijers CHW, van Basten JP, Somford DM. Prostate Cancer Prostatic Dis; 2022 Mar 10; 25(1):65-70. PubMed ID: 34471231 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]